You are currently viewing the summary.
View Full TextVia AAAS ID
This article is available to AAAS members. If you are a AAAS Member use your via AAAS ID and password to log in. Not a member? Click here to join.
Summary
A new class of anti-HIV drugs called protease inhibitors offers the most promising therapy so far. In combination with other antiviral drugs, they can reduce virus loads to undetectable levels. The manufacturers of the two leading protease inhibitors, Merck and Abbott, took different routes but arrived at the finishing post at almost exactly the same time.
